Research shows that cost-plus pricing can lower drug costs dramatically, depending on where in the supply chain the markup is applied.
|Articles|July 21, 2003
New flu vaccine caters to the "needle-phobic"
Just in time for the 2003/2004 flu season, clinicians will be able to offer their "needle phobic" patients the first cold-adaptive, live-attenuated influenza vaccine (CAIV) that is administered as a nasal spray. The FDA recently approved influenza virus vaccine live, intranasal (FluMist, MedImmune Vaccines/Wyeth Vaccines) for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, 5 to 17 years old, and healthy adults, 18 to 49 years old. The vaccine will be available in pharmacies beginning in the late summer to early fall.
Advertisement
Advertisement
Related to this article
Medicaid and Part D low-income subsidy enrollment narrowed some gaps, but much of the disparity occurred within the same plans.
In part 1 of our midterm election FAQ series, AJ Barbarito, Esq, breaks down ongoing legal developments for pharmacists and what a change in Congressional control could mean for the profession.
A modeling study projects that a structured lifestyle program for adults with prediabetes would be cost-effective and likely cost saving.
As a government price-setting formula, the same arithmetic has produced the opposite result.
Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.
Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.
Pharmacists face burnout and financial strain as PBMs take big cuts, prompting urgent calls for reform to protect patient care and community pharmacies.
Advertisement
Advertisement